dromlakhani Perform radionuclide bone scan to assess disease extent
STEP 1 — Gather Information
Confirm diagnosis of Paget's disease via plain radiographs of symptomatic or suspicious skeletal regions and evaluate serum total alkaline phosphatase (ALP) or specific bone formation/resorption markers if liver disease suspected. Collect history of bone pain, deformities, fractures, or incidental radiographic findings.
STEP 2 — Rule In / Rule Out
Is this a newly diagnosed patient with no prior assessment of skeletal involvement? If yes, proceed to bone scan for extent mapping; if extent already known or a scan was recently performed, skip bone scan and rely on existing imaging.
STEP 3 — Classify or Stratify
Classify disease extent by number of skeletal sites involved (monostotic vs polyostotic) and note any asymptomatic foci detected on scintigraphy that are not apparent on plain radiographs or clinically.
STEP 4 — Decide
Perform a whole‑body radionuclide bone scan (technetium‑99m‑MDP scintigraphy) to map all sites of increased osteoblastic activity, document the extent, and use findings to guide further management (e.g., treatment planning, surveillance).
Clinical Guardrails / Mimics / Pitfalls
Do not repeat the bone scan routinely for monitoring; repeat only if assessing treatment response when biochemical markers are normal or to evaluate change in extent. Avoid interpreting degenerative joint disease or old fractures as Paget lesions without correlating with clinical and radiographic context. Do not use bone scan as a primary diagnostic tool; plain radiographs remain first‑line for diagnosis. Do not rely solely on scan to gauge biochemical activity; uptake reflects osteoblastic activity, not necessarily resorption.
Concrete Clinical Example
A 70‑year‑old woman presents with an incidental lytic lesion on a thoracic spine X‑ray and elevated ALP. Plain radiographs confirm Paget’s disease of the vertebral body. A radionuclide bone scan reveals additional asymptomatic uptake in the right femur and left iliac crest, classifying her disease as polyostotic with three involved sites and prompting initiation of bisphosphonate therapy.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910